Capivasertib: A Novel AKT Inhibitor Approved for Hormone-Receptor-Positive, HER-2-Negative Metastatic Breast Cancer

CONCLUSION: Integration of capivasertib into clinical practice is ongoing; intermittent dosing and favorable toxicity are attractive for future novel combination prospective trials.PMID:38566315 | DOI:10.1177/10600280241241531
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Source Type: research